Abstract
Objective: To observe and evaluate the therapeutic effect of anti-tuberculosis (anti-TB) chemicals and Compound Astragalus Capsule (CAC) in combinedly treating drug resistant pulmonary tuberculosis (DR-TB).Methods: Ninety-two patients with DR-TB were equally randomized into the treated group (treated with combination therapy) and the control group (treated with anti-TB chemicals alone). The therapeutic course for both groups was 18 months. Therapeutic effects between the two groups were compared at the end of the therapeutic course. Sputum bacterial negative rate, focal absorption effective rate, cavity closing rate, 10-day symptom improving rate, the incidence of adverse reaction and 2-year bacteriological recurrence rate between the two groups were compared.Results: In the treated group, the sputum bacterial negative conversion rate was 84.8%, focal absorption effective rate 91.3%, cavity closing rate 58.7% and 10-day symptom improving rate 54.4%, while in the control group, the corresponding rates were 65.2%, 73.9%, 37.0% and 26.1%, respectively. Comparison between the groups showed significant difference in all the parameters (P<0.05,P<0.05,P<0.05 andP<0.01). The incidence of adverse reaction and 2-year bacteriological recurrence rate in the treated group were 23.9% and 2.6% respectively, while those in the control group 50.0% and 16.7%, which were higher than the former group with significant difference (P<0.01 andP<0.05, respectively).Conclusion: The therapeutic effect of combined treatment with anti-TB and CAC is superior to that of treatment with anti-TB chemicals alone, and the Chinese herbal medicine showed an adverse reaction alleviating effect, which provides a new therapy for DR-TB, and therefore, it is worth spreading in clinical practice.
Similar content being viewed by others
References
Li ZM, Wang SM. The epidemiologic trend of drug resistance tuberculosis. Chin J Tuberc Respir Dis 2000; 23 (2): 71–72.
Fox W. The current status of short course chemotherapy. Bull Int Union Tuberc 1978; 53: 268–270.
Branch of Tuberculosis, Chinese Association of Medicine. Chemotherapy of pulmonary tuberculosis. Chin J Tuberc Respir Dis 1982; 6: 381–384.
Drobniewski F, Pablos-mendez A, Raviglione MC. Epidemiology of tuberculosis in the world. Semin Respir Crit Care Med 1997; 18: 419–429.
Wang JH, Chen RS, editors. Clinical practical dictionary of Chinese material medica. Beijing: Jindun Publishing House, 2003: 28, 680.
Chen XQ, Jin YY, Tang G, editors. New compilatory pharmacology. 15th edition. Beijing: People’s Medical Publishing House, 2003: 716 -717.
Xiao ZJ, Cui XQ, Tao WC, et al. Measurement of Tlymphocyte subsets in drug resistant tuberculosis patients. Chin J Tuberc Respir Dis 1998; 21(7): 434.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yan, J., Xin, L., Zhi-yong, Y. et al. Clinical study of drugresistant pulmonary tuberculosis treated by combination of anti-tuberculosis chemicals and Compound Astragalus Capsule. Chin. J. Integr. Med. 10, 102–106 (2004). https://doi.org/10.1007/BF02836377
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02836377